TCI Gene Inc

Capital Structure and Liquidity TCI Gene Inc maintains a strong liquidity position, with a current ratio of 9.27, indicating ample short-term assets to cover liabilities. The company holds TWD 250.7 million in cash and equivalents, significantly exceeding its total liabilities of TWD 120.8 million. Its debt-to-equity ratio is 0.01, reflecting a conservative capital structure with minimal long-term debt exposure. ### Profitability and Returns The company's return on equity (ROE) is 4.56%, and its return on assets (ROA) is 4.01%, both below the median for the Healthcare Facilities & Services industry. While profitable, TCI Gene Inc's returns suggest moderate efficiency in generating returns from equity and total assets. ### Segments and Geographic Exposure TCI Gene Inc operates primarily in Taiwan, with no disclosed international revenue streams. Its business is concentrated in genetic and pharmacogenetic testing services, with no material diversification into other therapeutic or diagnostic areas. This geographic and product concentration increases exposure to local regulatory and market risks. ### Growth Trajectory The company's recent financial performance shows a revenue of TWD 273.6 million, with a net income of TWD 40.6 million. While operating cash flow is positive at TWD 151.3 million, free cash flow is negative at TWD 2.3 million, indicating reinvestment in operations or capital expenditures. The outlook for the current fiscal year suggests modest growth, with no significant revenue acceleration expected. ### Risk Factors Liquidity risk is low, supported by strong cash reserves and a low debt burden. Dilution risk is also low, with no immediate filing-based flags detected. However, the company's reliance on a single geographic market and limited product diversification could pose operational and regulatory risks. ### Recent Events No recent filings or transcripts have been disclosed that would indicate material changes in the company's operations or strategic direction. The company remains focused on its core genetic testing and cell therapy services.